BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 36824036)

  • 1. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Primary Biliary Cholangitis including Transplantation.
    Muzahim Y; Wakil A; Bassi M; Pyrsopoulos N
    Clin Liver Dis; 2024 Feb; 28(1):103-114. PubMed ID: 37945152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
    Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Primary biliary cholangitis].
    Soret PA; Chazouillères O; Corpechot C
    Rev Prat; 2021 Oct; 71(8):885-891. PubMed ID: 35147347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
    Zhang H; Li S; Feng Y; Zhang Q; Xie B
    Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenges of primary biliary cholangitis: What is new and what needs to be done.
    Terziroli Beretta-Piccoli B; Mieli-Vergani G; Vergani D; Vierling JM; Adams D; Alpini G; Banales JM; Beuers U; Björnsson E; Bowlus C; Carbone M; Chazouillères O; Dalekos G; De Gottardi A; Harada K; Hirschfield G; Invernizzi P; Jones D; Krawitt E; Lanzavecchia A; Lian ZX; Ma X; Manns M; Mavilio D; Quigley EM; Sallusto F; Shimoda S; Strazzabosco M; Swain M; Tanaka A; Trauner M; Tsuneyama K; Zigmond E; Gershwin ME
    J Autoimmun; 2019 Dec; 105():102328. PubMed ID: 31548157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy.
    Montano-Loza AJ; Corpechot C
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2241-2251.e1. PubMed ID: 32629125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
    Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
    BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Autoimmune mediated cholestatic liver diseases].
    Mayer LS; Käser R; Böttler T
    Dtsch Med Wochenschr; 2020 Mar; 145(5):296-305. PubMed ID: 32120404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
    Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
    Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population.
    Cançado GGL; Braga MH; Ferraz MLG; Villela-Nogueira CA; Terrabuio DRB; Cançado ELR; Nardelli MJ; Faria LC; Gomes NMF; de Oliveira EMG; Rotman V; de Oliveira MB; da Cunha SMCF; Mazo DFC; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; Pace FHL; Pessoa MG; Signorelli IV; Coral GP; Bittencourt PL; Levy C; Couto CA;
    Ann Hepatol; 2022; 27(1):100546. PubMed ID: 34600142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
    Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
    Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
    Gazda J; Drazilova S; Gazda M; Janicko M; Koky T; Macej M; Carbone M; Jarcuska P
    Dig Liver Dis; 2023 Oct; 55(10):1318-1327. PubMed ID: 36593158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.